Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparing Long-acting Insulins During Exercise in Type 1 Diabetes
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Buckinghamshire Healthcare NHS Trust
- Target Recruit Count
- 30
- Registration Number
- NCT01440439
- Locations
- 🇬🇧
Wycombe Hospital, High Wycombe, Buckinghamshire, United Kingdom
The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2012-08-14
- Lead Sponsor
- Ankara University
- Target Recruit Count
- 64
- Registration Number
- NCT01420692
- Locations
- 🇹🇷
Ankara University Medical Faculty Dept. of Endocrinology and Metabolism, Ankara, Turkey
A Comparison of Two Initial Dosing Formulas
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Diabetes Care Center
- Target Recruit Count
- 20
- Registration Number
- NCT01377155
- Locations
- 🇺🇸
Diabetes Care Center, Salinas, California, United States
Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2011-03-08
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT01310452
- Locations
- 🇨🇳
Zhong Shan Hospital, Fudan University, Shang hai, China
Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis
- First Posted Date
- 2011-01-06
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 120
- Registration Number
- NCT01271517
- Locations
- 🇸🇪
Division of Pediatrics, Karolinska University Hospital, Stockholm, Sweden
Insulin Detemir in Obesity Management
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 240
- Registration Number
- NCT01239550
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 30
- Registration Number
- NCT01232946
- Locations
- 🇺🇸
Indiana Clinical Research Center, Indianapolis, Indiana, United States
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 611
- Registration Number
- NCT01232491
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Samsun, Turkey
Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 30
- Registration Number
- NCT01186003
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
- Conditions
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 401
- Registration Number
- NCT01165684
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Trbovlje, Slovenia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.